newsfilter
← Latest News
PR Newswire·

AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 2022; fifth consecutive quarter of commercial (ex-DoD) sales volume growth for DSUVIA, with a 133% increase comp